Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path

Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to secure a decisive clinical win to enter the U.S. market.